Evidence map›Paper›PMID 37350945›Full record

ArticleFrontiers in oncology2023

Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination.

Chiara Masucci, Mauro Passucci, Emilia Scalzulli, Ida Carmosino, Marcello Capriata, Alessandro Costa, Claudia Ielo, Maurizio Martelli, Massimo Breccia

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Chiara MasucciDepartment of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Mauro PassucciDepartment of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Emilia ScalzulliDepartment of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Ida CarmosinoDepartment of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Marcello CapriataDepartment of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Alessandro CostaHematology Unit, Businco Hospital, Azienda di Rilievo Nazionale ed Alta Specializzazione (ARNAS) G. Brotzu, Cagliari, Italy.
Claudia IeloDepartment of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Maurizio MartelliDepartment of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Massimo BrecciaDepartment of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Policlinico Umberto I · ITSapienza University of Rome · ITAzienda di Rilievo Nazionale ed Alta Specializzazione · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe a case of second primary malignancy in a 65-year-old patient affected by polycythemia vera treated with the JAK 1/2 inhibitor ruxolitinib. The latter is recognized as a risk factor for the onset of non-melanoma skin cancers in many retrospective and perspective studies, but the concomitant use of ruxolitinib with new immunotherapies is very rarely reported, and the safety of this association is still not clear. In our case, ruxolitinib combined with the anti-PD-L1 avelumab demonstrated both safety and efficacy for hematological disease control and underlying carcinoma remission.

Indexed as

avelumabMerkel cell carcinomapolycytemia veraruxolitinibsecond malignancies

Identifiers

PMID37350945
PMCPMC10282638
OpenAlexW4379795920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.